Birds-of-a-Feather Round Table Discussion: U.S. National Patient Identifier (NPI) and its Impact to Clinical Trials
Date: Tuesday, August 18, 2020 Duration: One hour, starting at UTC 1500 (8amPDT, 10amCDT, 11amEDT, 4pmBST, 5pmCEST)
Facilitator: Ken Light, Clinscape
Open To: Staff from eClinical Forum member companies gratis. For registration information please send a note to email@example.com . (If you are not an eCF member, please review our website www.eclinicalforum.org/membership for membership information or contact firstname.lastname@example.org )
Background: eClinical Forum webinar sessions focus on the details of a specific topic. All participants are encouraged to share information and ask questions. Anyone from an eCF member company can participate, gratis. The facilitator will [try to] keep the subject on track and prompt discussion and information sharing.
For This Topic:
In 1996, HIPAA legislation called for the development of a national patient identifier system that would give each person in the United States a permanently assigned, unique number to be used across the entire spectrum of the national healthcare system. That project was never funded by congress, but just last year (June, 2019) Congress voted to appropriate $99 billion dollars to an HHS bill that included creation of a National Patient Identifier.
Ken Light will review this topic, and oversee a group dialog around the benefits, challenges, and impact related to healthcare and clinical trials. The agenda for this session includes:
- What is NPI and why is it needed?
- History of NPI in the U.S. - Why U.S. doesn’t have one yet
- Why NPI is used in other countries but not used in the U.S.
- Benefits and Challenges
- Short discussion of how this will be used, helpful, applied in our world of clinical trials
- Global Trials
- How will this apply to global trials - will the use of a U.S. NPI just complicate things?
- Any other complicating factors/risks?
- How this might be best implemented, keeping in mind the requirements of GDPR, HIPAA, Part-11, blinded studies, etc.
- Group Discussion, Questions, Ideas